Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection

John T. Lafin, Alexander P. Kenigsberg, Xiaosong Meng, Dreaux Abe, Anna Savelyeva, Nirmish Singla, Solomon L. Woldu, Yair Lotan, Ryan J. Mauck, Cheryl M. Lewis, Vitaly Margulis, Daniel Wong, Liwei Jia, Payal Kapur, Lin Xu, Ryan W. Speir, Gregory T. Chesnut, A. Lindsay Frazier, Douglas W. Strand, Nicholas ColemanMatthew J. Murray, James F. Amatruda, Aditya Bagrodia

Research output: Contribution to journalLetterpeer-review

2 Scopus citations

Abstract

Existing tumor markers for testicular germ cell tumor (TGCT) cannot detect the presence of pure teratoma. Serum miRNAs have strong performance detecting other subtypes of TGCT. Previous reports suggest high levels of miR-375 expression in teratoma tissue. The purpose of this study was to explore the role of serum miRNA, including miR-375, in detecting the presence of teratoma at postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). We prospectively collected presurgical serum from 40 TGCT patients undergoing PC-RPLND (21 with teratoma at RPLND and 19 with no evidence of disease). We examined the utility of serum miR-375-3p and miR-375-5p by quantitative polymerase chain reaction, and searched for other putative serum miRNAs with small RNA sequencing. The area under the receiver operating characteristic curve (AUC) and univariate analyses were utilized to evaluate test characteristics and predictors of teratoma. Both serum miR-375-3p and miR-375-5p exhibited poor performance (miR-375-3p: 86% sensitivity, 32% specificity, AUC: 0.506; miR-375-5p: 55% sensitivity, 67% specificity, AUC: 0.556). Teratoma at orchiectomy was the only predictor of PC-RPLND teratoma. Small RNA sequencing identified three potentially discriminatory miRNAs, but further validation demonstrated no utility. Our results confirm prior reports that serum miR-375 cannot predict teratoma, and suggest that there may not exist a predictive serum miRNA for teratoma. Patient summary: We found that serum miR-375 cannot detect the presence of teratoma at postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). We are also unable to find any other serum miRNAs predictive of pure teratoma at PC-RPLND. Hence, the lack of a reliable circulating marker of teratoma remains a critical clinical need.

Original languageEnglish (US)
Pages (from-to)83-87
Number of pages5
JournalEuropean Urology Open Science
Volume26
DOIs
StatePublished - Apr 2021

Keywords

  • MicroRNA
  • Retroperitoneal lymph node dissection
  • Serum biomarker
  • Teratoma

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection'. Together they form a unique fingerprint.

Cite this